Omega Diagnostics announced that it is deferring its preliminary results, which were expected on 19 August, until September to give further time to gain clarity regarding certain ongoing commercial discussions and other post-balance sheet events. The company confirmed that the FY 2019 results were as indicated at the 17 April trading update and that trading in Q1 2020 is in line with expectations. More exciting and relevant to the investment case, however, is confirmation that it has received
16 Aug 2019
Omega Diagnostics - Trading update - VISITECT CD4 purchase order
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Omega Diagnostics - Trading update - VISITECT CD4 purchase order
Cambridge Nutritional Sciences PLC (CNSL:LON) | 3.8 0 0.0% | Mkt Cap: 9.16m
- Published:
16 Aug 2019 -
Author:
Mark Brewer -
Pages:
3
Omega Diagnostics announced that it is deferring its preliminary results, which were expected on 19 August, until September to give further time to gain clarity regarding certain ongoing commercial discussions and other post-balance sheet events. The company confirmed that the FY 2019 results were as indicated at the 17 April trading update and that trading in Q1 2020 is in line with expectations. More exciting and relevant to the investment case, however, is confirmation that it has received